Human lung carcinomas express Fas ligand - PubMed (original) (raw)
. 1997 Mar 15;57(6):1007-12.
Affiliations
- PMID: 9067260
Human lung carcinomas express Fas ligand
G A Niehans et al. Cancer Res. 1997.
Abstract
To reach a clinically detectable size, neoplasms must be able to suppress or evade a host immune response. Activated T cells may enter apoptosis in the presence of Fas ligand (FasL) (1), and tissue expression of FasL has been shown to contribute to immune privilege in the eye and testis (2, 3). We have demonstrated that all human lung carcinoma cell lines tested (16 of 16) express a Mr 38,000 protein consistent with FasL by immunoblotting, whereas the majority of resected tumors (23 of 28) show positive staining for FasL by immunohistochemistry. DNA sequencing of reverse transcription-PCR products from lung cancer cells and resected lung tumors confirms the presence of human FasL mRNA in these neoplastic tissues. Furthermore, lung carcinoma cells are capable of killing a Fas-sensitive human T cell line (Jurkat) in coculture experiments; this killing was inhibited by a recombinant form of the soluble portion of the Fas receptor (FasFc). FasL expression by neoplastic cells represents a potential mechanism for peripheral deletion of tumor-reactive T-cell clones.
Similar articles
- Human pancreatic adenocarcinomas express Fas and Fas ligand yet are resistant to Fas-mediated apoptosis.
Ungefroren H, Voss M, Jansen M, Roeder C, Henne-Bruns D, Kremer B, Kalthoff H. Ungefroren H, et al. Cancer Res. 1998 Apr 15;58(8):1741-9. Cancer Res. 1998. PMID: 9563493 - Fas ligand is expressed in normal breast epithelial cells and is frequently up-regulated in breast cancer.
Müllauer L, Mosberger I, Grusch M, Rudas M, Chott A. Müllauer L, et al. J Pathol. 2000 Jan;190(1):20-30. doi: 10.1002/(SICI)1096-9896(200001)190:1<20::AID-PATH497>3.0.CO;2-S. J Pathol. 2000. PMID: 10640988 - Fas ligand is expressed on human squamous cell carcinomas of the head and neck, and it promotes apoptosis of T lymphocytes.
Gastman BR, Atarshi Y, Reichert TE, Saito T, Balkir L, Rabinowich H, Whiteside TL. Gastman BR, et al. Cancer Res. 1999 Oct 15;59(20):5356-64. Cancer Res. 1999. PMID: 10537320 - Frequent loss of Fas expression and function in human lung tumours with overexpression of FasL in small cell lung carcinoma.
Viard-Leveugle I, Veyrenc S, French LE, Brambilla C, Brambilla E. Viard-Leveugle I, et al. J Pathol. 2003 Oct;201(2):268-77. doi: 10.1002/path.1428. J Pathol. 2003. PMID: 14517844 - Human pancreatic cancer cells express non-functional Fas receptors and counterattack lymphocytes by expressing Fas ligand; a potential mechanism for immune escape.
Elnemr A, Ohta T, Yachie A, Kayahara M, Kitagawa H, Ninomiya I, Fushida S, Fujimura T, Nishimura G, Shimizu K, Miwa K. Elnemr A, et al. Int J Oncol. 2001 Jan;18(1):33-9. Int J Oncol. 2001. PMID: 11115536
Cited by
- Fas ligand expression in colon cancer: a possible mechanism of tumor immune privilege.
Zhang W, Ding EX, Wang Q, Zhu DQ, He J, Li YL, Wang YH. Zhang W, et al. World J Gastroenterol. 2005 Jun 21;11(23):3632-5. doi: 10.3748/wjg.v11.i23.3632. World J Gastroenterol. 2005. PMID: 15962391 Free PMC article. - Immunohistochemical study on Fas and Fas ligand in skin wound healing.
Guan DW, Ohshima T, Kondo T. Guan DW, et al. Histochem J. 2000 Feb;32(2):85-91. doi: 10.1023/a:1004058010500. Histochem J. 2000. PMID: 10816072 - Apoptosis: targets in pancreatic cancer.
Westphal S, Kalthoff H. Westphal S, et al. Mol Cancer. 2003 Jan 7;2:6. doi: 10.1186/1476-4598-2-6. Mol Cancer. 2003. PMID: 12605713 Free PMC article. Review. - Fas-ligand: privilege and peril.
Green DR, Ware CF. Green DR, et al. Proc Natl Acad Sci U S A. 1997 Jun 10;94(12):5986-90. doi: 10.1073/pnas.94.12.5986. Proc Natl Acad Sci U S A. 1997. PMID: 9177153 Free PMC article. Review. No abstract available. - p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs.
Müller M, Wilder S, Bannasch D, Israeli D, Lehlbach K, Li-Weber M, Friedman SL, Galle PR, Stremmel W, Oren M, Krammer PH. Müller M, et al. J Exp Med. 1998 Dec 7;188(11):2033-45. doi: 10.1084/jem.188.11.2033. J Exp Med. 1998. PMID: 9841917 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical
Research Materials
Miscellaneous